Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors

PURPOSE: Lifirafenib is an investigational, reversible inhibitor of B-RAF(V600E), wild-type A-RAF, B-RAF, C-RAF, and EGFR. This first-in-human, phase I, dose-escalation/dose-expansion study evaluated the safety, tolerability, and efficacy of lifirafenib in patients with B-RAF– or K-RAS/N-RAS–mutated...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Jayesh, Gan, Hui, Barrow, Catherine, Jameson, Michael, Atkinson, Victoria, Haydon, Andrew, Millward, Michael, Begbie, Stephen, Brown, Michael, Markman, Ben, Patterson, William, Hill, Andrew, Horvath, Lisa, Nagrial, Adnan, Richardson, Gary, Jackson, Christopher, Friedlander, Michael, Parente, Phillip, Tran, Ben, Wang, Lai, Chen, Yunxin, Tang, Zhiyu, Huang, Wendy, Wu, John, Zeng, Dewan, Luo, Lusong, Solomon, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325368/
https://www.ncbi.nlm.nih.gov/pubmed/32182156
http://dx.doi.org/10.1200/JCO.19.02654

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325368/
https://www.ncbi.nlm.nih.gov/pubmed/32182156
http://dx.doi.org/10.1200/JCO.19.02654

Ejemplares similares